What Aurora Pharmaceutical does

Aurora Pharmaceutical, Inc. is a privately-held veterinary pharmaceutical manufacturer headquartered at 1196 Highway 3 South, Northfield, Minnesota, that develops, manufactures, and distributes FDA-approved generic and branded animal health products across six species verticals: equine, porcine, poultry, bovine, companion animals, and a small human health line. The portfolio spans six therapeutic categories — antibiotics (e.g., EQUISUL-SDT®, TiaGard® 12.5%), pain management (EquiCoxib™/firocoxib), parasiticides (DectoGard™, EpriGard®, REVOLT®, BARRIER®), reproductive products (ALTREN®, SwineMate®, OvuGel®, CLARITY® A.I. jelly), wound care and antiseptics (BARRIER® Wound Care, PRO-TEC® chlorhexidine cleansers), and stress/hydration supplements (BALANCE, ORAL-PRO® D3/E, oregano). The company operates GMP-certified manufacturing at its single Northfield facility and explicitly positions around first-generic FDA approvals (DectoGard as the first generic doramectin topical solution; EquiCoxib as the generic equivalent to EQUIOXX® Paste) and affordable alternatives to brand-name veterinary drugs.

The business model is direct-to-customer via an authorized field sales representative network that calls on livestock producers, veterinarians, and pet owners, supplemented by a self-serve VET PORTAL for veterinary professionals and phone/email ordering for smaller accounts. Products are sold primarily in the United States with differentiated labeling for international markets, and pricing is not publicly disclosed — customers must contact sales — but the company's value proposition centers on competitive pricing of FDA-approved formulations against branded incumbents. Customer segments are diversified across commercial livestock (beef, dairy, swine, poultry), the equine show/performance industry, companion animal owners and veterinary clinics, and a minor human health line (Oral-Pro® Pyrantel Pamoate).

Underlying technology is conventional small-molecule veterinary pharmaceutical formulation and manufacturing rather than biologs or novel modalities; proprietary features are described as advanced green formulation/delivery systems, multi-species formulation expertise, and quality-controlled manufacturing. Aurora has launched four products in 2024 (DectoGard, EquiCoxib, KLENTZ, TiaGard 12.5%), with leadership in place under CEO/President Michael Strobel and CFO Lori Happel, ~$7.46M in cumulative disclosed equity funding (2011 and 2015 rounds), 11–50 employees, and a stated DVM Student Scholarship Program scaling from $75K (2023) to $100K (2026).

Name

Aurora Pharmaceutical

Legal name

Aurora Pharmaceutical, Inc.

Website

https://aurorapharmaceutical.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Aurora Pharmaceutical is a private, GMP-certified veterinary pharmaceutical manufacturer in Northfield, Minnesota that develops, produces, and sells FDA-approved generic and branded animal health products — including antibiotics, parasiticides, NSAIDs, reproductive drugs, wound care, and supplements — across equine, bovine, porcine, poultry, companion animal, and limited human markets in the United States.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

akta.pro secondary industries

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF), Pet Pharmaceuticals & Veterinary Supply Distribution (CRAOAKAD)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Livestock medications
• Pet parasiticides
• FDA-approved generics

Headquarters

HQ city

Northfield

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Veterinary Pharmaceutical Products: Aurora Pharmaceutical generates revenue through the sale of veterinary pharmaceutical products across multiple animal health categories including antibiotics, pain management, parasite control, reproductive health, wound care, and stress management solutions for equine, porcine, poultry, bovine, and companion animals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Aurora Pharmaceutical develops, manufactures, and markets FDA-approved veterinary pharmaceutical products across multiple animal health categories, including antibiotics, pain management, parasiticides, reproductive health, wound care, and stress/hydration supplements. The portfolio covers equine, porcine, poultry, bovine, companion animals, and a limited human health line, with products sold through authorized sales representatives, a VET PORTAL for veterinarians, and direct contact channels primarily in the United States.

Product overview

Aurora Pharmaceutical is a veterinary pharmaceutical company offering a comprehensive portfolio of animal health products across six species categories (Equine, Porcine, Poultry, Bovine, Pets, and Human). The product line includes antibiotics (EQUISUL-SDT®, TiaGard®), pain management (EquiCoxib™), parasiticides (DectoGard™, EpriGard®, REVOLT®, BARRIER®), reproductive products (ALTREN®, SwineMate®, OvuGel®, CLARITY® A.I. Lubricating Jelly), wound care (BARRIER® Wound Care), stress/hydration supplements (BALANCE®), vitamins (Oral-Pro® D3 Plus E), and general veterinary health products (PRO-TEC® antiseptics, CLARITY® Ultrasound Gel). The company operates with a focus on FDA-approved generic formulations and affordable alternatives to brand-name veterinary medications, supported by a state-of-the-art manufacturing facility in Northfield, Minnesota.

Differentiator

Problem solved

Functional benefit

Brands

• EQUISUL-SDT®: Sulfadiazine/Trimethoprim antibiotic for horses
• EquiCoxib™
• ALTREN®
• SwineMate®
• DectoGard™
• EpriGard®
• CocciAid®
• TiaGard® 12.5%
• REVOLT®
• BARRIER®
• KLENTZ™
• OvuGel®
• BALANCE
• CLARITY®
• PRO-TEC®
• Oral-Pro®

Products and services

• EQUISUL-SDT® (Sulfadiazine/Trimethoprim)

Quantifiable outcome

• Daily Balance administration increased water consumption by 10% in horses
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Virbac: Virbac is a French global animal health company producing pharmaceuticals, vaccines, and diagnostics for companion and livestock animals. Comparable as a multi-species veterinary pharmaceutical manufacturer serving similar end markets as Aurora, with broader geographic reach and larger product portfolio.
• Ceva Santé Animale: Ceva is one of the largest independent veterinary pharmaceutical companies globally, with strong positions in poultry, swine, and companion animal health. Aurora's poultry (CocciAid) and swine (TiaGard, SwineMate) franchises overlap directly with Ceva's core therapeutic categories.
• Phibro Animal Health: Phibro is a publicly-traded animal health and nutrition company with a broad portfolio including parasiticides, vaccines, and nutritional specialties for livestock and poultry. Highly comparable to Aurora's livestock and poultry product mix, though much larger and publicly listed.
• Vetoquinol: Vetoquinol is a global veterinary pharmaceutical company with a broad portfolio of therapeutics, parasiticides, and specialty products across companion and production animals. Directly comparable to Aurora as a multi-species veterinary pharma manufacturer, though significantly larger and globally diversified.
• Dechra Pharmaceuticals (Elanco): Dechra was a global veterinary pharmaceutical company specializing in companion animal and equine therapeutics, acquired by Elanco in 2024. Directly comparable to Aurora's equine franchise (EquiCoxib is a generic of EQUIOXX, marketed by Boehringer/Merial in Dechra's overlap space).
• Elanco Animal Health: Elanco is one of the largest global animal health companies with deep franchises in livestock parasiticides (eprinomectin via Ivomecat Eprinex) and companion animal therapeutics. Aurora's EpriGard (eprinomectin pour-on) and EquiCoxib directly compete with Elanco's product portfolio.

Direct peers

• Huvepharma: Huvepharma is a privately-held animal health and nutrition company with strong positions in livestock pharmaceuticals (especially anti-infectives and parasiticides) and poultry coccidiostats — directly comparable to Aurora's EpriGard, TiaGard, and CocciAid franchises.
• Norbrook: Norbrook is a privately-held veterinary pharmaceutical manufacturer focused on generic and branded anti-infectives, parasiticides, and anti-inflammatories for livestock and companion animals. Highly comparable to Aurora's generic-first, multi-species manufacturing model, headquartered in Northern Ireland.
• Bimeda: Bimeda is a private veterinary pharmaceutical manufacturer with strong positions in livestock, equine, and companion animal generics globally. The most directly comparable peer to Aurora in terms of business model (multi-species generics manufacturer), scale, and customer base, with significant overlap in parasiticides and antibiotics.

Regional players

• Kyoritsu Seiyaku: Kyoritsu Seiyaku is a Japanese veterinary pharmaceutical manufacturer specializing in livestock, poultry, and aquaculture therapeutics. Comparable to Aurora's livestock/poultry pharmaceutical manufacturing business model but operates primarily in Japan and Asia-Pacific rather than the U.S. market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/AuroraPharmaceutical
• LinkedInlinkedin.com/company/aurora-pharmaceutical
• Instagraminstagram.com/aurorapharmaceuticalinc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurora Pharmaceutical